These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 14644845

  • 1. CNS: sex steroids and SERMs.
    Bernardi F, Pluchino N, Stomati M, Pieri M, Genazzani AR.
    Ann N Y Acad Sci; 2003 Nov; 997():378-88. PubMed ID: 14644845
    [Abstract] [Full Text] [Related]

  • 2. Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women.
    Florio P, Quirici B, Casarosa E, Lombardi I, Luisi M, Genazzani AD, Petraglia F, Genazzani AR.
    Gynecol Endocrinol; 2001 Oct; 15(5):359-66. PubMed ID: 11727358
    [Abstract] [Full Text] [Related]

  • 3. Effects of the new generation selective estrogen receptor modulator EM-652 and oral administration of estradiol valerate on circulating, brain, and adrenal beta-endorphin and allopregnanolone levels in intact fertile and ovariectomized rats.
    Bernardi F, Stomati M, Luisi S, Pieri M, Labrie F, Riccardo Genazzani A.
    Fertil Steril; 2002 May; 77(5):1018-27. PubMed ID: 12009361
    [Abstract] [Full Text] [Related]

  • 4. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.
    Vogelvang TE, van der Mooren MJ, Mijatovic V, Kenemans P.
    Drugs; 2006 May; 66(2):191-221. PubMed ID: 16451093
    [Abstract] [Full Text] [Related]

  • 5. Selective estrogen modulators in menopause.
    Gambacciani M.
    Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
    [Abstract] [Full Text] [Related]

  • 6. Endocrinology of menopausal transition and its brain implications.
    Genazzani AR, Bernardi F, Pluchino N, Begliuomini S, Lenzi E, Casarosa E, Luisi M.
    CNS Spectr; 2005 Jun; 10(6):449-57. PubMed ID: 15908899
    [Abstract] [Full Text] [Related]

  • 7. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC, Gapstur S, Morrow M.
    J Natl Cancer Inst; 2001 Oct 03; 93(19):1449-57. PubMed ID: 11584060
    [Abstract] [Full Text] [Related]

  • 8. Use of SERMs for treatment in postmenopausal women.
    Pinkerton JV, Thomas S.
    J Steroid Biochem Mol Biol; 2014 Jul 03; 142():142-54. PubMed ID: 24373794
    [Abstract] [Full Text] [Related]

  • 9. Raloxifene analog LY 117018 effects on central and peripheral beta-endorphin.
    Genazzani AR, Bernardi F, Stomati M, Rubino S, Giardina L, Luisi S, Monteleone P, Genazzani AD, Luisi M, Petraglia F.
    Gynecol Endocrinol; 1999 Aug 03; 13(4):249-58. PubMed ID: 10533160
    [Abstract] [Full Text] [Related]

  • 10. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.
    Draper MW.
    Ann N Y Acad Sci; 2003 Nov 03; 997():373-7. PubMed ID: 14644844
    [Abstract] [Full Text] [Related]

  • 11. SERMs: evolutionary chemistry, revolutionary biology.
    Miller CP.
    Curr Pharm Des; 2002 Nov 03; 8(23):2089-111. PubMed ID: 12171520
    [Abstract] [Full Text] [Related]

  • 12. Estrogen, cognition and female ageing.
    Genazzani AR, Pluchino N, Luisi S, Luisi M.
    Hum Reprod Update; 2007 Nov 03; 13(2):175-87. PubMed ID: 17135285
    [Abstract] [Full Text] [Related]

  • 13. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
    Kastelan D, Giljevic Z, Kraljevic I, Korsic M.
    Med Hypotheses; 2006 Nov 03; 67(5):1052-3. PubMed ID: 16790322
    [Abstract] [Full Text] [Related]

  • 14. [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives].
    Simoncini T, Mannella P, Genazzani AR.
    Recenti Prog Med; 2003 Feb 03; 94(2):51-6. PubMed ID: 12908369
    [Abstract] [Full Text] [Related]

  • 15. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
    Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M, Serrano-Blanco A, Teba F, Usall J.
    Eur Neuropsychopharmacol; 2014 Feb 03; 24(2):223-31. PubMed ID: 24342775
    [Abstract] [Full Text] [Related]

  • 16. Selective oestrogen receptor modulators--current and future brain and behaviour applications.
    Halbreich U, Kahn LS.
    Expert Opin Pharmacother; 2000 Dec 03; 1(7):1385-98. PubMed ID: 11249472
    [Abstract] [Full Text] [Related]

  • 17. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
    Muchmore DB.
    Oncologist; 2000 Dec 03; 5(5):388-92. PubMed ID: 11040275
    [Abstract] [Full Text] [Related]

  • 18. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F, Lopes P.
    Presse Med; 2002 Sep 07; 31(28):1323-8. PubMed ID: 12355995
    [Abstract] [Full Text] [Related]

  • 19. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels.
    Bernardi F, Pluchino N, Pieri M, Begliuomini S, Lenzi E, Puccetti S, Casarosa E, Luisi M, Genazzani AR.
    Neuroendocrinology; 2006 Sep 07; 83(5-6):348-59. PubMed ID: 16931878
    [Abstract] [Full Text] [Related]

  • 20. Selective modulation of postmenopausal women: cutting the Gordian knot of hormone replacement therapy with breast carcinoma.
    Diamanti-Kandarakis E, Sykiotis GP, Papavassiliou AG.
    Cancer; 2003 Jan 01; 97(1):12-20. PubMed ID: 12491500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.